GlassScriptPhysician profile
Ladislas Lazaro
NPI 1336137215
$264,708.24
in general payments reported to CMS, 2019-2025
35 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $42K · 2021: $25K · 2022: $26K · 2023: $29K · 2024: $31K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $16K · Food and Beverage: $9,185 · Consulting Fee: $400 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,915.00 |
| Travel and Lodging | $16,039.64 |
| Food and Beverage | $9,184.50 |
| Consulting Fee | $400.00 |
| Education | $365.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $239,568.30 | 2019-2025 | Evenity, Prolia, Enbrel |
| Abbvie INC. | $13,200.69 | 2019-2025 | |
| Janssen Biotech, INC. | $1,914.71 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,547.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,026.93 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $908.91 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $843.44 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $735.51 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $590.61 | 2019-2025 | Sotyktu, Orencia |
| Novartis Pharmaceuticals Corporation | $578.98 | 2019-2025 | |
| Ucb, INC. | $504.36 | 2019-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $436.01 | 2023-2025 | Idacio |
| Ani Pharmaceuticals, INC. | $378.11 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $376.97 | 2020-2025 | Acthar |
| Pacira Therapeutics, INC. | $370.97 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $270.57 | 2019-2024 | Actemra |
| Regeneron Healthcare Solutions, INC. | $227.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.95 | 2019-2025 | Cyltezo, Ofev |
| Genzyme Corporation | $137.81 | 2020-2023 | |
| Fidia Pharma USA INC. | $120.72 | 2021-2022 | |
| Radius Health, INC. | $120.38 | 2019 | |
| Allergan, INC. | $111.09 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $90.85 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $78.77 | 2020-2025 | Strensiq |
| Eisai INC. | $65.84 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $45.81 | 2019 | |
| Organon LLC | $37.22 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $35.73 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $35.64 | 2021-2023 | Arcalyst |
| Idorsia Pharmaceuticals US INC | $33.42 | 2023 | Quviviq |
| Celgene Corporation | $30.31 | 2019 | |
| Kyowa Kirin, INC. | $24.12 | 2025 | |
| Celltrion USA INC. | $23.74 | 2023 | Yuflyma |
| Ultragenyx Pharmaceutical INC. | $20.35 | 2021 | |
| Biocon Biologics INC | $14.04 | 2024 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ladislas Lazaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.